Revert

Project evolution

COMPASS project: local press release

Article by the Editor PadovaOggi (PO) 29 January 2 ...

COMPASS Project Kick-Off meeting

The COMPASS project, a collaborative effort among ...

A new project funded by the CBE JU with NSB as implementing partner

It is a pleasure to announce that NEROSUBIANCO SRL ...

Celebrating 20 years of Innovation at Nerosubianco srl

Celebrating 20 Years of Innovation at Nerosubianco ...

Digital Healthcare

Digital innovation plays a strategic role in many ...

Greene 4.0 Project Kick-Off meeting

On 12 and 13 April 2023, the kick-off meeting of t ...

Why joining the DITA Project? – IPN

Watch the video and find out why our Portuguese pa ...

Why joininig the DITA Project? – Kempten University of Applied Sciences

Watch the video and find out why our German partne ...

New VSM2 release

We are pleased to inform you that in cooper ...

I4MS: A EUROPEAN INITIATIVE THAT COMBINES ICT AND THE MANUFACTURING SECTOR

Among the initiatives promoted by the Europ ...

REVERT focuses on an innovative AI-based decision support system utilizing the experience and real-world data from several European general hospitals.

The main goal is to develop an improved and innovative model of combinatorial therapy that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable mCRC

  • 7 medical oncology units involved in the clinical trials
  • 1 Predictive algorithm ‘trained’ through retrospective evaluation of the clinical profiles of patients
  • Detailed analysis based on the study of consolidated data – which have been classified in the Revert database – on metastatic patients from European biobanks
Project preparatory phase:
  • Develop the comprehensive financial management framework for the lead partner and assist with the overall Grant and Consortium Agreement closing process
  • Support the set up of a Joint Research Unit
Project implementation:
  • Permanently align budget and operations
  • Financial Reporting & Amendments management
  • Monitor clinical studies, assess technoloygy readiness of the platform and identify follow-up opportunities
CONTACT US TODAY

Let's get in touch

Are you ready for a better, more productive business?
NAME and SURNAME(Obbligatorio)
Consent(Obbligatorio)
Having read the notice I allow/not allow NEROSUBIANCO S.R.L. to use the e-mail address of the interested party to send commercial communications containing information on its services, as well as promotions or invitations to events in which the owner will participate.
Questo campo serve per la convalida e dovrebbe essere lasciato inalterato.